advertisement
Abstract #10041 Published in IGR 5-3
Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma
Tsukamoto H; Jian K; Tajamatsu M; Okada K; Mukai S; Tsumamoto Y; Mishima HKJapanese Journal of Ophthalmology 2003; 47: 526-528
PURPOSE: To investigate when an α-1 blocker, bunazosin, has an additive effect on lowing intraocular pressure (IOP) when added topically to latanoprost treatment in patients with glaucoma. METHODS: Bunazosin twice a day was added topically to the treatment of 12 patients with glaucoma who had been instilling latanoprost once a day for more than one month. IOP was measured and adverse events were checked two, four, and eight weeks after the addition of bunazosin to their treatment. RESULTS: One of the 12 patients dropped out during the course of the study. Therefore, 11 patients were included in the analysis of IOP, and 12 in the analysis of adverse events. IOP was significantly decreased (p = 0.008, Wilcoxon signed rank test) from 18.2 ± 3.4 to 16.6 ± 3.5 mmHg eight weeks after the addition of bunazosin. Adverse events were seen in five of the 12 patients. CONCLUSION: Bunazosin has an additive effect on lowering IOP when added topically to latanoprost treatment in glaucoma patients.
Dr. H.K. Mishima, Department of Ophthalmology and Visual Sciences, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. hkmishi@hiroshima-u-ac.jp
Classification:
11.3.5 Other (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
